ViiV Healthcare receives EU Marketing Authorisation for Tivicay, a treatment for children living with HIV in Europe

▴ ViiV Healthcare receives EU Marketing Authorisation for Tivicay, a treatment for children living with HIV in Europe
Tivicay contains dolutegravir, an integrase strand transfer inhibitor for use in combination with other antiretroviral agents for the treatment of HIV

ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi Limited as shareholders, recently announced that the European Commission has granted Marketing Authorisation for Tivicay (dolutegravir) 5mg dispersible tablets, which are used in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in paediatric patients (treatment-naïve or -experienced but INSTI- naïve) aged at least four weeks and weighing at least 3kg. This authorisation includes updated dosing recommendations, for Tivicay (dolutegravir) film-coated tablets (10mg, 25mg and 50mg) for children 6 years and older and weighing at least 14kg, bringing these in line with the World Health Organization weight bands.

Deborah Waterhouse, CEO of ViiV Healthcare, said: “Today’s authorisation is a really important milestone towards enabling children to have access to age-appropriate formulations of HIV medicine. Globally there are approximately 1.7 million children living with HIV and around 100,000 children dying each year from AIDS which is why we won’t stop doing all that we can to ensure that no child living with HIV is left behind.”

The EU Marketing Authorisation follows the US Food and Drug Administration (FDA) approval of Tivicay PD in 2020[1], providing an age-appropriate formulation of dolutegravir for a younger population to help to close the gap between HIV treatment options available for adults and children.

Amanda Ely, CEO of CHIVA (Children’s HIV Association) said: “As an organisation, we continue our efforts to help support young people and families living with HIV manage the challenges of lifelong treatment and today’s authorisation helps to do this. Today’s news is a positive step forward in helping the many children and infants who may struggle to take their medicines in tablet form.”

The Marketing Authorisation is based on data from the ongoing P1093[2] and ODYSSEY[3] (PENTA20) studies, which are being conducted in collaboration with international paediatric research networks, IMPAACT and PENTA-ID.

Tivicay contains dolutegravir, an integrase strand transfer inhibitor for use in combination with other antiretroviral agents for the treatment of HIV. Integrase inhibitors inhibit HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle.

Tags : #ViiVHealthcare #LatestNewsonViiVHealthcare15thJan #LatestPharmaNews15thJan #GlaxoSmithKline #PfizerInc #ShionogiLtd #ChildrenWithHIV #TreatmentforHIV #USFDA

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Traditionally, men were seen as more profit-oriented in business, but now women are proving they are equally capable - Rahul Jain, a top Indian business coach.September 25, 2023
4-Year-Old Girl Gets New lease of life at American Oncology Institute (AOI) Hyderabad with Haploidentical Stem Cell Transplantation September 25, 2023
Silver Oaks International Schools to provide succor to the underprivileged through its ‘Silver Oaks Street Store’ initiative!September 25, 2023
Sri Pullela Gopichand addressing freshers at OMC, emphasised on focussing on goals to achieve success! September 25, 2023
Fall Prevention Experience Centre for the Elderly Inaugurated at LVPEISeptember 25, 2023
Your Retina, Your Responsibility: 5 Tips For Maintaining Eye HealthSeptember 25, 2023
Puducherry Government's Noble Initiative: Empowering Underprivileged Students in Medical EducationSeptember 23, 2023
Title: From Dialysis to Freedom: Aditi's Inspiring kidney Transplant StorySeptember 23, 2023
Narayana Health Achieves Guinness World Record with 3,797 ECGs Conducted in a DaySeptember 23, 2023
Beyond Spoken Words, The Beauty of Sign Language: Celebrating the International Day of Sign LanguageSeptember 23, 2023
Dengue: Symptoms, Warnings & NS1 antigen TestSeptember 23, 2023
EQUIPPP welcomes Mr. Guru R. Sowle as an AdvisorSeptember 23, 2023
Exploring Patient Safety : Empowering patients , Ensuring safetySeptember 22, 2023
Manipal Hospitals Expands Its Footprint: A Game-Changer for Healthcare in Eastern IndiaSeptember 22, 2023
Empowering Palliative Care: Workshop Highlights from Pain Awareness Month 2023September 22, 2023
Studying Alzheimer's 7 Stages on World Alzheimer's DaySeptember 21, 2023
AIIMS Takes the Lead in Transforming Indian Healthcare with 'Ayushman Bhav'September 21, 2023
New study finds stressful jobs may double heart disease risk in womenSeptember 21, 2023
Global Women’s Health Innovation Conference 2023September 21, 2023
Our favourite cheese might just be a delicious way to boost our brainpower: Japanese Study Reveals Surprising FindingsSeptember 20, 2023